Embrace the future of trademark practice with our AI-powered solution, providing a transformative approach to both trademark prosecution and litigation.
Maximize your brand's impact with AI-powered solutions for brand content creation, management and protection. (Invite only to pilot clients)
Like a Google reverse image search and text search, but for trademarks. Search for existing marks in USPTO...
Catch potential conflicts as soon as they’re filed. Everything you need in one place.
Discover threats to your clients’ trademarks from over 60 million eCommerce listings.
Most advanced image recognition for trademark law
Case research has never been easier thanks to the largest knowledge graph in trademark law
For the first time, trademark lawyers and professionals have their own “achievement profiles”
Reconsidering portfolio management as revenue management
Hear what your peers love about Huski.ai for their trademark practices.
Browse potential refusal cases in pending applications against existing marks
Browse new trademark applications everyday. Discover business trends
The only ranking in the industry that is based on big data analysis of attorneys’ performance on trademark applications and litigations
The only ranking in the industry that is based on big data analysis of brand litigation records and brand impact factor
Your source of data insights, technology progress, and industry trend of trademark law.
We are AI engineers and intellectual property litigation professionals. As innovators ourselves, we believe that creativity and innovation are what drive us forward, and we want all individuals, professionals, and businesses of all sizes enjoy and benefit from the process of innovation.
Huski.ai exists to make brand creation and protection easy with cutting-edge AI.
Built by AI experts in Silicon Valley who worked on self-driving cars and other cutting-edge tech innovations, Huski.ai is developing unprecedented technologies for trademark prosecution and protection, ultimately transforming trademark and brand protection for all.
We deeply appreciate the media's recognition about our work. It's a great motivation to keep us moving forward.
U.S Class(es): 005, 006, 018, 044, 046, 051, 052
Class Status: Active
Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of major depressive disorder; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor;